A New Standard of Care for Improving Patient Outcomes
PT/INR patient self-testing is approved by Medicare (CMS) and most private insurers for these conditions requiring warfarin oral anticoagulation:
Clinical benefits of self-testing:
Helps maintain patients in therapeutic range, which may reduce the potential for drug-related complications and emergency room visits
Reducing the potential for drug-related complications and ER visits may have a positive impact on costs associated with anti-coagulation
Provides timely alert to clinicians when patients are out of range
Provides greater support for anticoagulation therapy compliance:
Recent study in the New England Journal of Medicine cites warfarin as the leading cause of emergency room admissions among the elderly.
By contacting patients with reminders to test if weekly results are not received, Philips Patient Self-Testing service offers clinicians and their patients a high degree of support for anticoagulation therapy.
When testing patients with mechanical heart valves, Medicare advises: “In order to achieve time in therapeutic range of greater than 90%, a patient most likely needs to test once a week.” 1
Learn about recently published research on patient self-testing
1 Decision Memo for Prothrombin Time (INR) Monitor for Home Anticoagulation Management. (#CAG-00087N) National Coverage Analysis. Baltimore, MD: Centers for Medicare and Medicaid Services; September 18, 2001